Materials that respond to endogenous stimuli are being leveraged to enhance
spatiotemporal control in a range of biomedical applications from drug delivery to diagnostic …

Drug delivery to central nervous system (CNS) diseases is very challenging since the
presence of the innate blood–brain barrier (BBB) and the blood-cerebrospinal fluid barrier …

Rapid cut‐off of blood supply in diseases involving thrombosis is a major cause of morbidity
and mortality worldwide. However, the current thrombolysis strategies offer limited results …

Conventional thrombolytic drugs for vascular blockage such as tissue plasminogen activator
(tPA) are challenged by the low bioavailability, off-target side effects and limited penetration …

The poor drug delivery to cerebral ischemic regions is a key challenge of ischemic stroke
treatment. Inspired by the intriguing blood–brain barrier (BBB)-penetrating ability of 4T1 …

Rational design of nanomedicine to accelerate thrombolysis and sequentially avoid
thrombolysis-mediated reperfusion injury is still a challenge. Here, we develop a biomimetic …

Ischemic stroke leads to high disability and mortality. The limited delivery efficiency of most
therapeutic substances is a major challenge for effective treatment of ischemic stroke …

Thrombotic occlusions of blood vessels are responsible for life-threatening cardiovascular
disorders such as myocardial infarction, ischemic stroke, and venous thromboembolism …

Ischemic stroke is a vascular central nervous system (CNS) disease that leads a disability
and death. Thrombolysis and neuroprotection are the primary treatment strategies of …

In thrombotic diseases, the effects of reactive oxygen species (ROS)‐mediated oxidative
stress as a “perpetrator” in thrombosis must be resolved. Accordingly, an insufficient …